Phytomedicine
Volume 14, Issue 4 , Pages 289-300 , 10 April 2007

Acetylcholinesterase inhibitors from plants

  • Pulok K. Mukherjee

      Affiliations

    • Department of Pharmacy, Pharmacognosy Research Laboratories, Franklin-Wilkins Building, King's College London, 150 Stamford Street, London SE1 9NH, UK
    • School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
    • Corresponding Author InformationCorresponding author. School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India. Tel./fax:+913324146046.
    • ,
  • Venkatesan Kumar

      Affiliations

    • School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
    • ,
  • Mainak Mal

      Affiliations

    • School of Natural Product Studies, Department of Pharmaceutical Technology, Jadavpur University, Kolkata 700032, India
    • ,
  • Peter J. Houghton

      Affiliations

    • Department of Pharmacy, Pharmacognosy Research Laboratories, Franklin-Wilkins Building, King's College London, 150 Stamford Street, London SE1 9NH, UK

References 

  1. Ahmad W, Ahmad B, Ahmad M, Iqbal Z, Nisar M, Ahmad M. In vitro inhibition of acetylcholinesterase, butyrylcholinesterase and lipoxygenase by crude extract of Myricaria elegans Royle. J. Biol. Sci. 2003;3:1046–1049
  2. Andrade MT, Lima JA, Pinto AC, Rezende CM, Carvalho MP, Epifanio RA. Indole alkaloids from Tabernaemontana australis (Muell. Arg) Miers that inhibit acetylcholinesterase enzyme. Bioorg. Med. Chem. 2005;13:4092–4095
  3. Andrisano V, Bartolini M, Gotti R, Cavrini V, Felix G. Determination of inhibitors’ potency (IC50) by a direct high performance liquid chromatographic method on an immobilized acetylcholinesterase column. J. Chromatogr. B. 2001;753:375–383
  4. Anonymous. Compendium of Pharmaceuticals and Specialties. 25th ed. Toronto, Canada: Canadian Pharmacists Association; 2000;
  5. Ashani Y, Grunwald J, Kronman C, Velan B, Shafferman A. Role of tyrosine 337 in the binding of huperzine A to the active site of human acetylcholinesterase. Mol. Pharmacol. 1994;45:555–560
  6. Brenner GM. Pharmacology. Philadelphia: W.B. Saunders Company; 2000;
  7. Brlihlmann C, Marston A, Hostettmann K, Carrupt PA, Testa B. Screening of non-alkaloidal natural compounds as acetylcholinesterase inhibitors. Chem. Biodivers. 2004;1:819–829
  8. Chung YK, Heo HJ, Kim EK, Kim HK, Huh TL, Lim Y, et al. Inhibitory effect of ursolic acid purified from Origanum majorana L on the acetylcholinesterase. Mol. Cells. 2001;11:137–143
  9. Das A, Shanker G, Nath C, Pal R, Singh S, Singh HK. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba anticholinesterase and cognitive enhancing activities. Pharmacol. Biochem. Behav. 2002;73:893–900
  10. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet. 1976;2:1403
  11. Da-Yuan Z, Dong-Lu B, Xi-Can T. Recent studies on traditional Chinese medicinal plants. Drug Dev. Res. 1996;39:147–157
  12. DeKosky ST, Harbaugh RE, Schmitt FA, Bakay RA, Chui HC, Knopman DS. Cortical biopsy in Alzheimer's disease: diagnostic accuracy and neurochemical, neuropathological and cognitive correlations. Ann. Neurol. 1992;32:625–632
  13. Ellman GL, Courtney KD, Andres V, Featherstone RM. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961;7:88–95
  14. Enz A, Amstutz R, Boddeke H, Gmelin G, Malanowski J. Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease. Prog. Brain Res. 1993;98:431–438
  15. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Damaraju CV. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet. 2002;359:1283–1290
  16. Foye WO, Lemke TL, Williams DA. Principles of Medicinal Chemistry. fourth ed. USA: Williams and Wilkins; 1995;
  17. Giacobini E. Long term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer's disease. J. Neural Transmission Suppl. 2002;181–187
  18. Gottwald MD, Rozanski RI. Rivastigmine a brain-region selective acetylcholinesterase inhibitor for treating Alzheimer's disease: review and current status. Expert Opin. Invest. Drugs. 1999;8:1673–1682
  19. Hillhouse BJ, Ming DS, French CJ, Neil Towers GH. Acetylcholine esterase inhibitors in Rhodiola rosea. Pharm. Biol. 2004;42:68–72
  20. Howes MJ, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function Pharmacology. Biochem. Behav. 2003;75:513–527
  21. Howes MR, Perry NSL, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother. Res. 2003;17:1–18
  22. Ingkaninan K, Best D, Heijden VD, Hofte AJP, Karabatak B, Irth H, et al. High-performance liquid chromatography with on-line coupled UV, mass spectrometric and biochemical detection for identification of acetylcholinesterase inhibitors from natural products. J. Chromatogr. A. 2000;872:61–73
  23. Ingkaninan K, Temkitthawon P, Chuenchom K, Yuyaem T, Thongnoi W. Screening for acetylcholinesterase inhibitory activity in plants used in Thai traditional rejuvenating and neurotonic remedies. J. Ethnopharmacol. 2003;89:261–264
  24. Karczmar A. Invited review: anticholinesterases: dramatic aspects of their use and misuse. Neurochem. Int. 1998;32:401–411
  25. Kasa P, Rakonczay Z, Gulya K. The cholinergic system in Alzheimer's disease. Prog. Neurobiol. 1997;52:511–535
  26. Kelly CA, Harvey RJ, Cayton H. Drug treatments for Alzheimer's disease. Br. Med. J. 1997;314:693–694
  27. Khalid A, Haq ZU, Ghayur MN, Feroz F, Rahman AU, Gilani AH, et al. Cholinesterase inhibitory and spasmolytic potential of steroidal alkaloids. J. Steroid Biochem. Mol. Biol. 2004;92:477–484
  28. Kim DK. Inhibitory effect of corynoline isolated from the aerial parts of Corydalis incisa on the acetylcholinesterase. Arch. Pharm. Res. 2002;25:817–819
  29. Kim DK, Lim JP, Yang JH, Eom DO, Eun JS, Leem KH. Acetylcholinesterase inhibitors from the roots of Angelica dahurica. Arch. Pharm. Res. 2002;25:856–859
  30. Kim DK, Lee KT, Baek NI, Kim SH, Park HW, Lim JP, et al. Acetylcholinesterase inhibitors from the aerial parts of Corydalis speciosa. Arch. Pharm. Res. 2004;27:1127–1131
  31. Kishnani PS, Sullivan JA, Walter BK, Spiridigliozzi GA, Doraiswamy PM, Krishnan KRR. Cholinergic therapy for Down's syndrome. Lancet. 1999;353:1064–1065
  32. Lee KY, Sung SH, Kim YC. New acetylcholinesterase-inhibitory pregnane glycosides of Cynanchum atratum roots. Helvetica Chim. Acta. 2003;86:474–483
  33. Lopez S, Bastida J, Viladomat F, Codina C. Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts. Life Sci. 2002;71:2521–2529
  34. Marston A, Kissling J, Hostettmann K. A rapid TLC bioautographic method for the detection of acetylcholinesterase and butyrylcholinesterase inhibitors in plants. Phytochem. Anal. 2002;13:51–54
  35. Melzer D. New drug treatment for Alzheimer's diseases: lessons for healthcare policy. BMJ. 1998;316:762–764
  36. Mukherjee PK. Evaluation of Indian traditional medicine. Drug Inf. J. 2001;35:620–623
  37. Oh MH, Houghton PJ, Whang WK, Cho JH. Screening of Korean herbal medicines used to improve cognitive function for anti-cholinesterase activity. Phytomedicine. 2004;11:544–548
  38. Orhan I, Sener B, Choudhary MI, Khalid A. Acetylcholinesterase and butyrylcholinesterase inhibitory activity of some Turkish medicinal plants. J. Ethnopharmacol. 2004;91:57–60
  39. Perry EK, Haroutunian V, Davis KL. Neocortical cholinergic activities differentiate Lewy body dementia from classical Alzheimer's disease. Neuroreport. 1994;5:747–749
  40. Perry EK, Pickering AT, Wang WW, Houghton PJ, Perry NSL. Medicinal plants and Alzheimer's disease: integrating ethnobotanical and contemporary scientific evidence. J. Altern. Complem. Med. 1998;4:419–428
  41. Perry N, Court G, Bidet N, Court J, Perry E. European herbs with cholinergic activities: potential in dementia therapy. Int. J. Geriatric Psychiatry. 1996;11:1063–1069
  42. Perry NSL, Houghton PG, Theolad AE, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J. Pharm. Pharmacol. 2000;52:895–902
  43. Perry NSL, Houghton PG, Sampson J, Theolad AE, Hart S, Lis-balchin M, et al. In vitro activities of Salvia lavandulaefolia (Spanish Sage) relevant to treatment of Alzheimer's disease. J. Pharm. Pharmacol. 2001;53:1347–1356
  44. Price DL. New perspectives on Alzheimer's disease. Neuroscience. 1986;9:489–512
  45. Rahman AU, Choudhary MI. Bioactive natural products as a potential source of new pharmacophores a theory of memory. Pure Appl. Chem. 2001;73:555–560
  46. Raves ML, Harel M, Pang YP, Silman I, Kozikowski AP, Sussman JL. Structure of acetylcholinesterase complexed with the nootropic alkaloid, (-)-huperzine A. Nat. Struct. Biol. 1997;4:57–63
  47. Rhee IK, Meent MV, Ingkaninan K, Verpoorte R. Screening for acetylcholinesterase inhibitors from Amaryllidaceae using silica gel thin-layer chromatography in combination with bioactivity staining. J. Chromatogr. A. 2001;915:217–223
  48. Rizzi A, Schuh R, Bruckner A, Cvitkovich B, Kremser L, Jordis U, et al. Enantiomeric resolution of galantamine and related drugs used in anti-Alzheimer therapy by means of capillary zone electrophoresis employing derivatized cyclodextrin selectors. J. Chromatogr. B. 1999;730:167–175
  49. Roddick JG. The acetylcholinesterase inhibitory activity of steroidal glycoalkaloids and their aglycones. Phytochemistry. 1989;28:2631–2634
  50. Scott LJ, Goa KL. Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000;60:1095–1122
  51. Schulz V. Ginkgo extract or cholinesterase inhibitors in patients with dementia: what clinical trial and guidelines fail to consider. Phytomedicine. 2003;10:74–79
  52. Siddiqui MF, Levey AI. Cholinergic therapies in Alzheimer's disease. Drugs of Future. 1999;24:417–444
  53. Sims NR, Bowen DM, Allen SJ, Smith CC, Neary D, Thomas DJ. Presynaptic cholinergic dysfunction in patients with dementia. J. Neurochem. 1983;40:503–509
  54. Siqueira IR, Fochesatto C, Lourenco da Silva A, Nunes DS, Battastini AM, Netto CA, et al. Ptychopetalum olacoides, a traditional Amazonian nerve tonic possesses anticholinesterase activity. Pharmacol. Biochem. Behav. 2003;75:645–650
  55. Sung SH, Kang SY, Lee KY, Park MJ, Kim JH, Park JH, et al. (+)-α-Viniferin, a stilbene trimer from Caragana chamlague inhibits acetylcholinesterase. Biol. Pharm. Bull. 2002;25:125–127
  56. Tang XC, Kindel GH, Kozikowski AP, Hanin I. Comparison of the effects of natural and synthetic huperzine-A on rat brain cholinergic function in vitro and in vivo. J. Ethnopharmacol. 1994;44:147–155
  57. Urbain A, Marston A, Queiroz EF, Ndjoko K, Hostettmann K. Xanthones from Gentiana campestris as new acetylcholinesterase inhibitors. Planta Med. 2004;70:1011–1014
  58. Wang T, Tang XC. Reversal of scopolamine-induced deficits in radial maze performance by (-)-huperzine A: comparison with E2020 and tacrine. Eur. J. Pharmacol. 1998;349:137–142
  59. Whitehouse PJ. Cholinergic therapy in dementia. Acta Neurol. 1993;149:42–45

PII: S0944-7113(07)00030-X

doi: 10.1016/j.phymed.2007.02.002

Phytomedicine
Volume 14, Issue 4 , Pages 289-300 , 10 April 2007

Article Tools

* Image Usage & Resolution